Comparative Pharmacology
Head-to-head clinical analysis: CIPRO HC versus KETEK.
Peer-Reviewed Evidence
Head-to-head clinical analysis: CIPRO HC versus KETEK.
CIPRO HC vs KETEK
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Ciprofloxacin inhibits bacterial DNA gyrase (topoisomerase II) and topoisomerase IV, preventing DNA replication and transcription; hydrocortisone suppresses inflammation via glucocorticoid receptor activation.
Telithromycin binds to the 50S subunit of bacterial ribosome, inhibiting protein synthesis by blocking peptide chain elongation.
Instill 3 drops into the affected ear(s) twice daily (morning and evening) for 7 days.
Telithromycin 800 mg orally once daily for 7-10 days.
None Documented
None Documented
Ciprofloxacin: 4-6 hours (prolonged to 6-9 hours in elderly or renal impairment). Hydrocortisone: 1-2 hours.
Terminal half-life (t½) is 9.8–10.6 hours in young healthy adults, allowing once-daily dosing. In elderly or severe hepatic impairment, t½ may be prolonged.
Ciprofloxacin: ~50-70% excreted renally as unchanged drug, ~15% as metabolites; ~20-30% eliminated via biliary/fecal route. Hydrocortisone: metabolized hepatically, renal excretion of metabolites.
Primarily fecal (≈70%) via biliary excretion of unchanged drug; renal excretion accounts for ≈13% (mostly unchanged), with additional minor metabolism (<30%).
Category C
Category C
Antibiotic/Corticosteroid Combination (Otic)
Antibiotic, Ketolide